Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Income from Continuing Operations (2018 - 2025)

Inmune Bio (INMB) has disclosed Income from Continuing Operations for 8 consecutive years, with 5474000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 42.18% to 5474000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 47383000.0 through Dec 2025, down 11.14% year-over-year, with the annual reading at 47383000.0 for FY2025, 11.14% down from the prior year.
  • Income from Continuing Operations hit 5474000.0 in Q4 2025 for Inmune Bio, up from 7433000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 4548000.0 in Q1 2021 to a low of 24571000.0 in Q2 2025.
  • Historically, Income from Continuing Operations has averaged 8743150.0 across 5 years, with a median of 7911000.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 211.06% in 2021 and later soared 42.18% in 2025.
  • Year by year, Income from Continuing Operations stood at 9030000.0 in 2021, then soared by 37.52% to 5642000.0 in 2022, then crashed by 48.51% to 8379000.0 in 2023, then fell by 12.98% to 9467000.0 in 2024, then skyrocketed by 42.18% to 5474000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for INMB at 5474000.0 in Q4 2025, 7433000.0 in Q3 2025, and 24571000.0 in Q2 2025.